amobarbital has been researched along with Chronic Kidney Failure in 1 studies
Amobarbital: A barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmacopoeia, 30th ed, p565)
amobarbital : A member of the class of barbiturates that is pyrimidine-2,4,6(1H,3H,5H)-trione substituted by a 3-methylbutyl and an ethyl group at position 5. Amobarbital has been shown to exhibit sedative and hypnotic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balasubramaniam, K | 1 |
| Mawer, GE | 1 |
| Pohl, JE | 1 |
| Simons, PJ | 1 |
1 other study available for amobarbital and Chronic Kidney Failure
| Article | Year |
|---|---|
Impairment of cognitive function associated with hydroxyamylobarbitone accumulation in patients with renal insufficiency.
Topics: Adult; Amobarbital; Barbiturates; Chromatography, Gas; Cognition; Cognition Disorders; Female; Human | 1972 |